Once damaged, it has limited ability to heal, leaving millions of people worldwide with permanent paralysis. However, a groundbreaking clinical trial in Japan has provided a glimmer of hope, showing ...

Researchers sought to determine whether using HRD sources for HSCT would be effective for pediatric patients with hematologic cancers compared with UCB sources.

It may be disturbing to characterize human bodies in such commodifying terms, but the unavoidable reality is that human ...

A novel regimen significantly reduced risk for moderate to severe chronic graft-versus-host disease for certain patients who ...

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

The following is a summary of “Improved survival in older patients with myeloid malignancies undergoing haploidentical ...

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

U.S. Completed OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematological Malignancies Hematological ...

Scientists at the Wisconsin National Primate Research Center (WNPRC) and the Morgridge Institute for Research at the University of Wisconsin–Madison have been at the forefront of stem cell research ...